Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.63 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | AOC2 | O75106 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | ACP3 | P15309 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3491722 | 0.86 | TAAR1 (0.57) | MEN1KMT2AMAPTSMYD3KDM4E | |
| SCHEMBL6850939 | 0.85 | MEN1 (0.67) | MEN1KMT2AMAPTSMYD3MAPK8 | |
| SCHEMBL7194491 | 0.84 | AOC2 (0.67) | MEN1KMT2AMAPTSMYD3KDM4E | |
| SCHEMBL23758509 | 0.83 | ALDH1A1 (0.62) | MEN1KMT2AMAPTSMYD3MAPK8 | |
| SCHEMBL30496803 | 0.83 | EPHX1 (0.59) | MEN1KMT2AMAPTSMYD3MAPK8 | |
| SCHEMBL966493 | 0.83 | EPHX1 (0.59) | MEN1KMT2AMAPTSMYD3MAPK8 | |
| SCHEMBL12472056 | 0.83 | MEN1 (0.63) | MEN1KMT2AMAPTSMYD3MAPK8 | |
| SCHEMBL21981024 | 0.83 | MEN1 (0.68) | MEN1KMT2AMAPTSMYD3MAPK8 | |
| SCHEMBL13753606 | 0.83 | MEN1 (0.63) | MEN1KMT2AMAPTSMYD3MAPK8 | |
| SCHEMBL13753362 | 0.83 | MEN1 (0.63) | MEN1KMT2AMAPTSMYD3MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3634406-B1 | 3,4,5-TRISUBSTITUTED-1,2,4-TRIAZOLES AND 3,4,5-TRISUBSTITUTED-3-THIO-1,2,4-TRIAZOLES AND USES THEREOF | BOARD OF TRUSTEES OF THE SOUTHERN ILLINOIS UNIV ON BEHALF OF SOUTHERN ILLINOIS UNIV EDWARDSVILLE (US) | 2023-09-06 | — | — | EP | disclosed |
| US-11136312-B2 | 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof | Board of Trustees of the Southern Illinois University (US) | 2021-10-05 | — | — | US | disclosed |
| US-11136312-B2 | 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof | Board of Trustees of the Southern Illinois University (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200165230-A1 | 3,4,5-Trisubstituted-1,2,4-Triazoles and 3,4,5-Trisubstituted-3-Thio-1,2,4-Triazoles and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-05-28 | — | — | US | disclosed |
| US-20200165230-A1 | 3,4,5-Trisubstituted-1,2,4-Triazoles and 3,4,5-Trisubstituted-3-Thio-1,2,4-Triazoles and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-05-28 | — | — | US | disclosed |
| CN-1191255-C | Benzodiazepine derivatives as GABA A receptor modulators | HOFFMANN LA ROCHE (CH) | 2005-03-02 | — | — | CN | disclosed |
| EP-1337535-B1 | BENZODIAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2004-06-09 | — | — | EP | disclosed |
| US-6743789-B2 | SUBSTITUTED IMIDAZO (1,5-A) (1,2,4) TRIAZOLO (4,3-D) (1,4) BENZODIAZEPINE DERIVATIVES ARE USEFUL FOR TREATING ALZHEIMER'S DISEASE; REACTING A BEZODIAZEPINE DERIVATIVE WITH A HYDRAZIDE DERIVATIVE TO FORM END PRODUCT | HOFFMANN-LA ROCHE INC. | 2004-06-01 | — | — | US | disclosed |
| CN-1474820-A | Benzodiazepine derivatives as GABA A receptor modulators | - | 2004-02-11 | — | — | CN | disclosed |
| EP-1337535-A2 | BENZODIAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-27 | — | — | EP | disclosed |
| US-20020103371-A1 | Substituted imidazo [1,5-a] [1,2,4] triazolo [4,3-d] [1,4] benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002040487-A2 | BENZODIAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-05-23 | — | — | WO | disclosed |
| US-5098922-A | Anticonvulsants | CIBA-GEIGY CORPORATION (US) | 1992-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103371-A1 | Substituted imidazo [1,5-a] [1,2,4] triazolo [4,3-d] [1,4] benzodiazepine derivatives | GABRA5, GABRA1, GABRA4 | MEN1 3485/4885KMT2A 1267/4885MAPT 2520/4885 |
| US-20200165230-A1 | 3,4,5-Trisubstituted-1,2,4-Triazoles and 3,4,5-Trisubstituted-3-Thio-1,2,4-Triazoles and Uses Thereof | SSTR4, SSTR3, SSTR5 | MEN1 1354/4885KMT2A 3857/4885MAPT 4291/4885 |
| US-11136312-B2 | 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof | SSTR4, SSTR3, SSTR5 | MEN1 1354/4885KMT2A 3857/4885MAPT 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.